Loading…
H.R. 6130119th CongressIn committeeLatest action Nov 19, 2025Decoded by AI · checked against the record
The plain-language version leads. The official text is always the reference.
Starting in 2028, Medicare would be required to cover FDA-approved blood tests that detect Alzheimer's and related dementias early.
45-second read · 4 questions answered below
This bill would require Medicare to cover blood-based tests that can detect Alzheimer's disease and related dementias before or in the early stages of symptoms, starting January 1, 2028. To qualify, a test must be FDA-approved or cleared and must analyze blood or other biological samples, including tests that look at genes, proteins, cell-free nucleic acids, or similar markers. The agency overseeing Medicare would decide which specific tests qualify, as long as results are comparable to the core blood-based tests described in the bill.
Medicare enrollees would be affected — generally people 65 and older, as well as certain people with disabilities.
Requiring coverage could remove out-of-pocket costs for these early detection tests for Medicare enrollees. People who could not otherwise afford these screenings may gain access to them.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.